Healthcare Private Placement and M&A Transactions Review Week Ending February 22, 2026

Altesa BioSciences: The company raised $75 million Series B venture funding in a deal led by Forbion on February 19, 2026, putting the company’s pre-money valuation at $115 million. Sanofi, Atlantic Partners, Pitango Venture Capital, Medicxi and other undisclosed investors also participated in the round. The company is a developer of antiviral medicines designed for the treatment of respiratory infections and global viral threats.

ProSomnus Sleep Technologies: The company raised $38 million of venture funding from Catalio Capital Management on February 18, 2026. The company is a manufacturer of custom-fitted oral medical devices intended to treat obstructive sleep apnea and snoring.

Pharaoh Neuro: The company raised $20 million of Series A venture funding in a deal led by Arboretum Ventures on February 18, 2026. Hatteras Venture Partners, IAG Capital Partners and Laerdal Million Lives Fund also participated in the round. The company is a developer of a medical device company intended for cerebrospinal fluid management.

Flinn: The company raised EUR 16.8 million of venture funding in a deal led by HV Capital Investors on February 19, 2026. Bertelsmann Investments, Speedinvest, SquareOne Venture Capital, and Cherry Ventures also participated in the round. The company is an operator of a medical management application intended to digitize and automize paper compliance trails.

Rainfall Health: The company raised $15 million of Series A venture funding in a deal led by Two Bear Capital on February 18, 2026. The company is a developer of a cloud-based digital health platform designed to provide patient-centric benefits management for people covered under government care.

GelMEDIX: The company raised $13.5 million of venture funding in a deal led by Safar Partners on February 17, 2026. HTL, TiE Angels Boston, Boston Harbor Angels, Beacon Angels and other undisclosed investors also participated in the round. The company is a developer of a light-activated injectable hydrogel scaffold platform used to support ocular regenerative therapies.

Berlin Heals: The company raised CHF 8.3 million of venture funding from undisclosed investors on February 19, 2026, putting the company’s pre-money valuation at CHF 111.67 million. The company is a developer of a cardiac implant device used to treat heart failure via electrical microcurrent therapy.

Step Pharma: The company raised $10 million of venture funding from European Innovation Council on February 19, 2026. The company is a developer of proprietary small molecule therapeutics designed for the treatment of auto-immune diseases via oral nucleotide synthesis inhibition targeting CTPS1.

Tozaro: The company received GBP 6 million of development capital from Mercia Asset Management and Mercia Ventures on February 16, 2026. The company is a developer of smart-polymer reagents used to support viral vector analytics, purification, and manufacturing for cell and gene therapy.

KLOwen Orthodontics: The company raised $8 million of venture funding from undisclosed investors on February 19, 2026. The company is a developer of orthodontic appliances used to deliver custom bracket prescriptions.

NED Medical: The company raised $8 million of Series-A venture funding from undisclosed investors on February 19, 2026, putting the company’s pre-money valuation at $23 million. The company is a developer of radioembolization medical technology designed to improve treatment outcomes for liver cancer.

Alume Biosciences: The company raised $6.9 million of Series C venture funding from undisclosed investors on February 18, 2026. The company is a developer of a nerve illumination technology designed to help doctors perform precision surgery.

Arbutus Medical: The company raised CAD 9.3 million of venture funding in a deal led by Crédit Mutuel Equity on February 17, 2026. CU Healthcare Innovation Fund, Nimbus Synergies, Genome British Columbia, MEDTEQ Invest and Threshold Impact also participated in the round. The company is a developer of power tools and sterile-packed kits used for surgical drilling and related orthopedic procedures.

Truentity Health: The company raised $5.4 million of venture funding from in the form of SAFE notes from Triangle Tweener Fund on February 18, 2026. The company is a developer of an AI-enabled clinical services platform used to automate clinical workflows and support reimbursable services such as remote patient monitoring.

Custom Surgical: The company raised EUR 3.5 million of venture funding in a deal led by Ventech on February 19, 2026. ZEISS International and other undisclosed investors also participated in the round. The company is a developer of hardware-agnostic imaging systems used to digitize ophthalmic slit lamps and surgical microscopes.

Akava Therapeutics: The company is in the process of raising venture funding on February 18, 2026. The company is a developer of small molecule therapeutics designed to inhibit protein aggregation, inhibit enzymes, and inhibit cancer for a variety of neurodegenerative diseases and cancers.

Corbotics: The company raised an undisclosed amount of venture funding from European Innovation Council on February 17, 2026. The company is a developer of an automated cardiac ultrasound acquisition system used to capture transthoracic echocardiography images.

Elumn8 Medical: The company raised Series C venture funding from undisclosed investors on February 18, 2026. The company is an operator of a medical technology company intended to develop advanced tools for treating complex heart conditions.

Ten63 Therapeutics: The company raised an undisclosed amount of venture funding from SF Express, Chugai Venture Fund and Gates Foundation on February 19, 2026. Yosemite, Cape Fear BioCapital, Black Opal Ventures, Draper Associates, Duke Capital Partners, Morpheus Ventures, Hatteras Venture Partners, Alexandria Venture Investments, RYSE Asset Management, K5 Global and Panorama also participated in the round. The company is a developer of remedial antineoplastic therapeutics used to target previously undruggable proteins.

Tripair: The company raised an undisclosed amount of venture funding from European Innovation Council on February 17, 2026. The company is a developer of an adaptive tricuspid valve repair device designed to treat structural heart valve diseases.

Masimo / Danaher: The company reached a definitive agreement to be acquired by Danaher for an estimated $9.9 billion on February 17, 2026. The company is a developer of noninvasive patient monitoring technologies used to measure physiologic parameters such as oxygen saturation via Signal Extraction Technology pulse oximetry.

Faeth / Sensei Biotherapeutics: The company was acquired by Sensei Biotherapeutics for an undisclosed amount on February 18, 2026. The company is a developer of oncology therapeutics used to target tumor metabolism and signaling.

LymphaTech / Tactile Medical: The company was acquired by Tactile Medical for $6.8 million on February 17, 2026. The company is a developer of 3D body scanning technology designed to diagnose lymphedema.

Augmedics / VB Spine: The company entered into a definitive agreement to be acquired by VB Spine, via its financial sponsors Barings and Viscogliosi Bros., through an LBO on February 16, 2026 for an undisclosed amount. The company is a developer of an augmented-reality surgical navigation system used to visualize patient anatomy and guide instrumentation during spine surgery.

Catalyst Clinical Research / Worldwide Clinical Trials: The company was acquired by Worldwide Clinical Trials, via its financial sponsors Kohlberg & Company, NB Capital Solutions, Crescent Capital Group and TJC, through an LBO on February 16, 2026 for an undisclosed amount. The company is an operator of a full-service, technology-enabled, oncology-focused contract research organization intended to serve the biotechnology, pharmaceuticals, and medical device companies.

Conformal / W. L. Gore and Associates: The company was acquired by W. L. Gore and Associates for an undisclosed amount on February 21, 2026. The company is a developer of a medical implant device designed to prevent stroke in patients with atrial fibrillation.

Medmain / Techmatrix: The company was acquired by Techmatrix for YEN 2.8 billion (approximately $18 million) on February 17, 2026. The company is a developer of a cloud-based platform designed to assist in digital pathology through AI-powered image analysis and remote diagnostics.